
    
      This is a Phase 1b/2, multicenter, open-label study of MEDI-575 to evaluate the dose,
      anti-tumor activity, safety, and pharmacology (pharmacokinetics, immunogenicity, and
      biomarkers) of MEDI-575 in combination with carboplatin/paclitaxel in subjects with
      previously untreated, advanced non-small cell lung cancer. This study has two phases: dose
      determination (Phase 1b) and randomization (Phase 2).
    
  